CAR T cell therapy is an immunotherapy that is effective in treating blood cancer. By closely investigating some of the immune cells generated during this therapy, known as CD4 T cells, scientists from the Institut Pasteur and Inserm, in collaboration with clinicians from the Paris Public Hospital Network (AP-HP), discovered that these cells are capable of remotely neutralizing tumor cells by producing interferon gamma (IFN-γ).
In order to understand its genetic causes and biological mechanisms, a new international study led by Inserm Research Director Nabila Bouatia-Naji at the Paris-Cardiovascular Research Center - PARCC (Inserm/Université Paris Cité) was set up. Its findings show the genetic causes that define the risk of SCAD to be very numerous and distributed across the entire patient genome.
Researchers from Inserm, Université Paris-Saclay and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ) with the Gustave Roussy Institute studied the impact of physical activity on the development of PD in nearly 100,000 women from the French cohort E3N followed up over 29 years.
The health outcomes of the nuclear tests performed in French Polynesia in the 1970s have been the subject of epidemiological studies at Inserm for several years. In a new publication, the scientists confirm these findings and conduct a risk prediction analysis showing that these nuclear tests could be responsible for 2.3% of the thyroid cancer cases.
In France, one third of emergency department (ED) visits are the result of trauma. In order to better understand the mechanisms and improve the management of trauma, researchers from Inserm and Université de Bordeaux at the Bordeaux Population Health Research Center, with teams from Bordeaux University Hospital, have developed an algorithm capable of classifying ED visits for trauma through the artificial intelligence (GPT) analysis of clinical reports.
Several months after infection with SARS-CoV-2, some patients still have symptoms: a phenomenon commonly referred to as "long COVID". Teams from Inserm and Université Paris Cité, in collaboration with the University of Minho in Braga (Portugal), have shown that this could be explained biologically by abnormalities of the immune system associated with the persistence of the virus in the mucous membranes.
For the first time, researchers from Institut Curie, the CNRS and Inserm have uncovered a previously unknown chain of biochemical reactions. This chain involves copper and leads to metabolic and epigenetic alterations that activate inflammation and tumorigenesis. But there is more; the research team developed a “drug prototype” capable of mitigating both the mechanisms of inflammation and the processes potentially involved in metastatic spread.